quinfamide

04/01/1980 - "A new intraluminal amebicide (Quinfamide) was tested to assess its effectivity and tolerance for treatment of non-dysenteric intestinal amebiasis. "
08/01/1980 - "Activity of quinfamide against natural infections of Entamoeba criceti in hamsters: a new potent agent for intestinal amoebiasis."
01/01/1996 - "An open comparative, prospective and randomized study was carried out to evaluate the efficacy and safety of quinfamide and etofamide in the treatment of intestinal amebiasis. "
01/01/1996 - "[Comparison of quinfamide vs etofamide in the Mexican population with intestinal amebiasis]."
01/01/1983 - "Quinfamide, a luminal amebicide, is a dichloroacetyl quinolol used to treat chronic and subacute intestinal amebiasis. "

08/01/1980 - "Activity of quinfamide against natural infections of Entamoeba criceti in hamsters: a new potent agent for intestinal amoebiasis."
03/01/2002 - "The present study was carried out to evaluate the effectiveness of nitazoxanide compared with that of quinfamide, mebendazole, or both in the treatment of intestinal protozoa and helminthic infections. "
03/01/2002 - "Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children."

01/01/1983 - "A study with quinfamide in the treatment of chronic amebiasis in adults."
01/01/1983 - "Quinfamide, a dichloroacetyl quinolol synthesized and tested at Sterling Winthrop Research Institute, is a potent luminal amebicide with potential utility for a one-day treatment of chronic and subacute amebiasis caused by Entamoeba histolytica. "
01/01/1983 - "Treatment of chronic amebiasis in pediatric patients with a suspension of quinfamide."

04/20/2002 - "The study participants who tested negative for cysts were divided into three groups: Group 1 had 102 patients who underwent quinfamide treatment and three CPS analyses after the 12 months of the study; Group 2 had 98 subjects who underwent the quinfamide treatment and three CPS analyses at months 3, 6, 9, and 12 after their entrance into the study; and Group 3 had 102 patients, who underwent the quinfamide treatment and series of three CPS analyses at months 6 and 12 of the study. "
04/20/2002 - "Those included in the study received a single 4.3-g/kg dose of quinfamide, and we performed PSC on days 5, 6, and 7 following dose administration to examine whether quinfamide had affected the presence of the cysts. "
04/20/2002 - "This study sought to examine whether the administration of quinfamide at 3- or 6-month intervals diminished the frequency of Entamoeba histolytica cysts in stool samples compared to controls. "

01/01/2000 - "metallic taste 3 to 5 days after administration of secnidazole) in mouth (p < 0.0001) were more common in the secnidazole group than in the quinfamide group. "